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Localization, mechanism and reduction of
renal retention of technetium-99m labeled
epidermal growth factor receptor-speciﬁc
nanobody in mice
Lea Olive Tchouate Gainkama*, Vicky Caveliersa,b, Nick Devoogdta,
Christian Vanhovea,b, Catarina Xaviera, Otto Boermand,
Serge Muyldermansc, Axel Bossuytb and Tony Lahouttea,b
Background: Nanobodies are single-domain antigen binding fragments derived from functional heavy-chain
antibodies elicited in Camelidae. They are powerful probes for radioimmunoimaging, but their renal uptake is
relatively high. In this study we have evaluated the role of megalin on the renal uptake of anti-EGFR 99mTc-7C12
nanobody and the potency of gelofusine and/or lysine to reduce renal uptake of 99mTc-7C12.
Methods: First we compared the renal uptake of 99mTc-7C12 in megalin-deﬁcient and megalin-wild-type mice using
pinhole SPECT/microCT and ex vivo analysis. The effect of gelofusine and lysine administration on renal accumulation
of 99mTc-7C12 was analyzed in CD-1 mice divided into lysine preload at 30min before tracer injection (LysPreload),
LysPreloadRgelofusine coadministration (LysPreloadRGeloCoad), lysine coadministration (LysCoad), gelofusine
coadministration (GeloCoad) and LysCoadRGeloCoad. The combined effect of gelofusine and lysine on tumor uptake
was tested in mice xenografts.
Results: Renal uptake of 99mTc-7C12 was 44.22W 3.46% lower in megalin-deﬁcient compared with megalin-
wild-type mice. In CD-1 mice, lysine preload had no effect on the renal retention whereas coinjection of lysine or
gelofusine with the tracer resulted in 25.12W 2.99 and 36.22W 3.07% reduction, respectively. The combined effect of
gelofusine and lysine was the most effective, namely a reduction of renal retention of 45.24W 2.09%. Gelofusine and
lysine coadministration improved tumor uptake.
Conclusion: Megalin contributes to the renal accumulation of 99mTc-7C12. Gelofusine and lysine coinjection with the
tracer reduces the renal uptake while tumor uptake is improved. Although this methodology allows for optimization
of imaging protocol using nanobodies, further improvements are needed before using these molecules for
radionuclide therapy. Copyright # 2010 John Wiley & Sons, Ltd.
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1. INTRODUCTION
Small antibody fragments are promising for tumor targeting
because their small size allows them to penetrate deep into
tumor tissues. For imaging applications they have the advantage
that they are more rapidly cleared from the circulation compared
with intact monoclonal antibodies, providing high tumor-to-
background ratios at relatively early time points (1). Moreover,
coupling with therapeutic radionuclides allows targeted radio-
nuclide therapy. Many different formats have been investigated
including nanobodies, minibodies, diabodies (1–4), scFvs, Fabs
and F(ab)2 (5,6). Each format has its own pharmacokinetic proﬁle
with a blood clearance that is largely dependent on themolecular
size. A size below the renal threshold for glomerular ﬁltration
(60 kDa) typically results in a high ﬁrst-pass renal clearance.
We are investigating radiolabeled nanobodies (derived from
the heavy chain antibodies of Camelidae) as a new group of
antibody-based agents for clinical molecular imaging and
radionuclide therapy. Nanobodies are small (15 kDa) intact antigen
binding fragments derived from single-domain heavy-chain
(wileyonlinelibrary.com) DOI:10.1002/cmmi.408
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antibodies. They are the smallest antibody-based fragments that
can be engineered at present and their small size enables them to
recognize unique hidden epitopes that are less accessible for
conventional antibodies (7). With the recent identiﬁcation of a
universal humanized nanobody scaffold, these probes are now
also ready for clinical translation (8,9). In our previous work
we identiﬁed 99mTc-7C12 nanobody (Ablynx NV) as the lead
compound for monitoring EGFR expression of cancer based on its
high tumor uptake, fast blood clearance and low liver uptake
(10,11). High-contrast images of EGFR-expressing lesions can be
obtained as early as 1 h post injection (p.i.). However, the organs
with the highest accumulation are the kidneys. This might limit
the sensitivity of detecting a speciﬁc molecular signal in the
vicinity of the kidneys. High renal accumulation is also a limiting
factor for applications of radionuclide therapy using nanobodies.
This problem is common to other small peptides and antibody
fragment-based probes. It is believed to be related to the
extensive apical endocytic apparatus of the renal proximal
tubule that is responsible for reabsorption of molecules ﬁltered in
the glomeruli. Several key receptors appear to be involved in
this function with megalin receptor as probably the most
important receptor in the endocytosis process (12). Megalin is a
600 kDa multiligand endocytic recepor belonging to the low-
density lipoprotein receptor. It is heavily expressed in the renal
proximal tubule and involved in protein reabsorption.
Several possible strategies to reduce renal reabsorption of
receptor-speciﬁc radiopharmaceuticals (peptides and antibody
fragments) have been successfully employed. These include
infusion of cationic amino acids (e.g. lysine, arginine or the
combination), modiﬁcations of physicochemical characteristics
of the agent such as introduction of a saccharide moiety, or
increasing the number of negative charges in the proteins or
peptides (13–15). Recently several groups also reported a renal
reduction of radiolabeled peptides using gelatin-based plasma
expanders like gelofusine (16–18).
The aim of this report was to investigate the role of themegalin
receptor in the accumulation of 99mTc-7C12 nanobody in the
kidneys and to test the possibility of reducing kidney retention by
L-lysine and/or gelofusine administration.
2. MATERIALS AND METHODS
2.1. Nanobody labeling
7C12 nanobody was a kind gift from Ablynx, Ghent, Belgium. It
was generated and puriﬁed as described previously (19). 7C12
was labeled as described by Gainkam et al. (10). Brieﬂy, 50mg of
7C12 was added to [99mTc(H2O)3(CO)3]
þ prepared using a Isolink
kit (Mallinckrodt Medical, Petten, The Netherlands) and the
mixture was incubated for 90min at 508C in a water bath. The
unreacted [99mTc(H2O)3(CO)3]
þ was separated from the labeled
compound using a NAP-5 column (GE Healthcare, Diegem,
Belgium) preequilibrated with 10ml phosphate buffered saline
(PBS) and passed through a 0.22mmMillipore ﬁlter (Millipore S.A./
N.V., Brussels, Belgium). The labeling efﬁciency was determined
by instant thin-layer chromatography (ITLC) in acetone and was
always more than 90%. The radiochemical purity of the used
tracer was always greater than 99%.
2.2. Cell culture and animal models
The human skin carcinoma cell line A431 was obtained from
EPO-GmbH (Berlin-Buch, Germany). It expresses about 2 106
EGFRmolecules per cell (20). The cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM),(Invitrogen, Paisley, UK) supple-
mented with 10% fetal bovine serum, L-glutamine (2mmol l1) and
PEST (penicillin 100 IU ml1 and streptomycin 100mg ml1), 1%
Naþpyruvate and 1% non-essential amino acids all obtained
from Invitrogen (Paisley, UK). The cells were collected with
trypsin–ethylenediamine tetraacetic acid (EDTA) 0.05% (Invitro-
gen). Cells were grown at 378C in a humidiﬁed air incubator
equilibrated with 5% CO2. Femalemegalin-deﬁcient andmegalin-
expressing mice were developed in the laboratory of Professor
Thomas Willnow (21,22); they were bred and PCR screened in the
laboratory of Professor Otto Boerman. Healthy male (ICR/CD1)
mice were purchased from Harlan (Horst, The Netherlands).
Tumor xenografts were obtained by inoculating A431 cells
(3 106) in 150ml PBS (pH 7.4) subcutaneously into the right
hind of 6-week-old athymic nude mice (Harlan) under the control
of 2.5% isoﬂurane (Abbott, Ottignies LLN, Belgium). Tumors were
allowed to grow for 10–14 days, when the diameter of the tumor
reached 0.5–1 cm. The study protocol was approved by the
ethical committee for animal research of our institution.
2.3. High-performance liquid chromatography
HPLC was performed using a Merck Hitachi L-7100 (VWR,
Haarsrode, Belgium) coupled to a UV–vis detector L-7400 (VWR,
Haarsrode, Belgium, detection wavelength 280 nm) and a
g-detector (LB 507 B, Berthold, BadWildbad, Germany). Analytical
separations were achieved by size exclusion chromatography
(SEC) on a Superdex 75 10/300 GL column (GE Healthcare, Upsala,
Sweden) preequilibrated with 0.01 M phosphate buffer (pH 7.4) at
a ﬂow rate of 0.5mlmin1.
2.4. In vitro stability
99mTc-7C12 (100ml, 37 MBq) was added to 900ml of human
plasma or 300ml PBS and incubated at 378C and room
temperature respectively. SEC-HPLC was performed at 6 and
24 h for serum sample and at 1 and 24 h for PBS.
2.5. In vivo stability
Nude athymic mice were intravenously injected with 39.42–67.33
MBq of 99mTc-7C12 and euthanized at 1 h p.i. with a lethal dose of
pentobarbital (Nembutal, CEVA, Brussels, Belgium). The kidneys,
urine and a blood sample were collected. The kidneys were
mashed in 0.25ml EBC buffer (170mM NaCl, 10mM EDTA, 50mM
Tris pH 7.4, 50mM NaF, 0.5% NP-40) supplemented with protease
inhibitor (Roche, Mannheim, Germany), incubated on ice for
20min and centrifuged at 48C for 15min at 14000 rpm. Urine was
ﬁltered through a Millex GV ﬁlter (0.22mm) before analysis.
The 99mTc-7C12 in urine or the supernatant of the kidneys
homogenate was analyzed by SEC-HPLC. The serum could not be
analyzed because no radioactivity could be detected.
2.6. Autoradiography
Kidneys were collected frommice injected with 99mTc-7C12 at 1 h
p.i., embedded in tissue-Tek1 OCTTM compound (Sakura Finetek,
Zoeterwoude, The Netherlands) and frozen immediately in
liquid nitrogen. Cryosections of 10mm were made at 208C.
Autoradiographic images (10min) of renal slices were acquired
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using the Microimager (Biospace, France). Images were visualized
with b-visionþ software (Biospace, France).
2.7. Renal uptake of 99mTc-7C12 in megalin-deﬁcient mice
Female C57Bl/6 megalin-deﬁcient and megalin-wild-type mice
were intravenously injected with 39.96–66.60 MBq of 99mTc-7C12
in 100ml PBS (containing 4.5mg 7C12). At 1 h p.i. mice were
anesthetized with a mixture of 18.75mg kg1 ketamine hydro-
chloride (Ketamine 10001, CEVA, Brussels, Belgium) and
0.5mg kg1 medetomidin hydrochloride (Domitor1, Pﬁzer,
Brussels, Belgium). Total body pinhole SPECT/microCT was
performed as described previously (10). Brieﬂy, microCT imaging
(Skyscan 1178, Aartselaar, Belgium) was followed by pinhole
SPECT (e.cam180 Siemens Medical Solutions, IL, USA) on separate
imaging systems and images were fused automatically using
six 57Co sources based on a mathematical software (23). MicroCT
images were reconstructed using ﬁltered backprojection (Nre-
con, Skyscan). Total body pinhole SPECT was performed using
a dual-headed gamma camera, mounted with two triple-
pinhole collimators (pinhole opening, 1.5mm) and images
were reconstructed using an iterative reconstruction algorithm
modiﬁed for the three-pinhole geometry. Images were viewed
and analyzed using AMIDE Medical Image Data Examiner soft-
ware (24). Regions of interest (ROI) were drawn around the total
body and the kidneys. The radioactivity in the ROIs was divided
by the injected activity corrected for decay, and further divided
by the kidney weight (obtained after dissection) and expressed as
percentage of injected activity per gram (%IA g1). The total
body retention (corrected for decay) at the time of imaging
was calculated as ({[counts in the total body – (counts in the
tailþ counts in the bladder)]/injected activity} 100) and
expressed as %IA. The tracer elimination was derived from the
total body retention. Immediately after pinhole SPECT, mice
were euthanized at 1.5 h p.i. with a lethal dose of pentobarbital.
The radioactivity in the blood, kidneys, liver, spleen and muscle
was measured in an automated gamma counter (Cobra II
Inspector 5003, Canberra-Packard, Illinois, USA) and expressed as
%IA per gram.
2.8. Effect of gelofusine and lysine on the renal uptake of
99mTc-7C12 in healthy mice
Gelofusine 40 g l1 was a kind gift from B-Braun Medical NV/SA
(Diegem, Belgium). An 800mgml1 lysine solution (Sigma
Aldrich GmbH, Steinheim, Germany) was prepared in 0.9% NaCl
and adjusted to pH 7.4 with HCl 6 M. Male ICR/CD1 mice (29–36 g)
were used to evaluate the effect of 40mg (0.3mmol) lysine and/
or 4mg (0.1mmol) gelofusine on kidney uptake of 99mTc-7C12. A
total of ﬁve experimental conditions were studied: (1) lysine
preload at 30min before tracer injection (LysPreload); (2) lysine
preload at 30min before tracer injectionþ gelofusine coadminis-
tered with the tracer (LysPreloadþGeloCoad); (3) lysine coadmi-
nistration with the tracer (LysCoad); (4) gelofusine coadministration
with the tracer (GeloCoad); and (5) lysineþ gelofusine co-admini-
stration (LysCoadþGeloCoad) with the tracer. A group of mice
injected with 99mTc-7C12 alone served as the control group. A
total of six mice were studied for each condition unless otherwise
stated. Mice were euthanized at 1.5 h post administration of the
tracer. The radioactivity in the kidneys was measured in an
automated gamma counter. The kidney uptake was calculated as
percentage of injected activity (%IA) corrected for decay. The
percentage of reduction of kidney uptake of 99mTc-7C12 was
calculated as follows:
% reduction ¼100 ½ð% uptake in control animal
%uptake in experimental conditionsÞ=
% uptake in control animal
2.9. Effect of combined gelofusine and lysine
administration on the biodistribution of 99mTc-7C12 in mice
bearing a tumor xenograft
Male athymic nude mice bearing A431 tumor xenograft were
used to evaluate the effect of LysCoadþGeloCoad on the
biodistribution of 99mTc-7C12 and particularly on tumor uptake.
Tumor-bearing mice were intravenously injected with either
32.56–54.39 MBq of 99mTc-7C12 in PBS (containing 2.5mg 7C12)
alone (control) or coinjected with a mixture of 150mg kg1 of
gelofusine and 1.2 g kg1 of lysine. At 1 h p.i., pinhole SPECT and
microCT images were obtained as described above. For image
analysis, regions of interest (ROI) were drawn around the total
body, kidneys, tumor and bladder on pinhole SPECT images
whereas ROI of contralateral muscle and liver were drawn on CT
images. The radioactivity in the ROIs was divided by the injected
activity corrected for decay and expressed as %IA per cubic
centimeter except for the kidneys, for which radioactivity was
expressed as %IA per gram. The tracer elimination corrected for
decay at the time of imaging was calculated as described
above. At 1.5 h p.i., the mice were euthanized with a lethal dose of
pentobarbital. Blood, liver, kidneys, spleen, contralateral muscle
and tumor were collected, weighed and their radioactivity
content recorded in a gamma counter together with a standard
of injected activity. The uptake in the tumor and other organs was
expressed as %IA per gram corrected for decay.
Blood samples were collected using a microcapillary at 1, 5, 10,
20, 40 and 60min p.i. of 99mTc-7C12 in both LysCoadþGeloCoad
and control group in order to determine the effect LysCoadþ
GeloCoad on blood clearance. The total blood volume (TBV) was
calculated as 7% of the total body weight. The biological half-lives
of 99mTc-7C12 in vivo were determined using the bi-exponential
non-linear regression of GraphPad Prism Software.
2.10. Statistical analysis
Uptake of 99mTc-7C12 in tumor, tissues and organs was expressed
as the mean standard error of the mean (SEM) and compared
by Mann–Whitney test for both imaging and ex vivo analysis
using GraphPad Prism software. The test was considered
statistically signiﬁcant when the p-value was <0.05.
3. RESULTS
3.1. Autoradiography
A representative autoradiogram of a kidney slice of a mouse
injected with 99mTc-7C12 and sacriﬁced at 1 h p.i. is shown in
Fig. 1. 99mTc-7C12 is mainly concentrated in the renal cortex.
3.2. Stability
After incubation in PBS and human plasma at 378C for up to 24 h,
only one major peak of radioactivity (>96%) was observed with
the same retention time (27min) as that of intact 99mTc-7C12
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(Fig. 2). In kidney and urine samples both intact tracer and
metabolites were detected. The proportion of metabolites was 90
and 98% in the urine and kidney sample respectively.
3.3. Renal retention of 99mTc-7C12 in megalin-deﬁcient
mice
The total body pinhole SPECT/microCT image of megalin-deﬁcient
mice showed less intense renal accumulation of radioactivity
(Fig. 3). Image quantiﬁcation at 1 h p.i. showed signiﬁcantly lower
renal retention of the tracer in megalin-deﬁcient compared with
megalin-expressing mice (105.84 6.54 vs 216.56 6.52%IA g1;
p< 0.05). Furthermore, tracer elimination in megalin-knockout
mice was 52.17 4.10 vs 21.75 1.51%IA in megalin-expressing
mice (p< 0.05). The ex vivo data of 99mTc-7C12 in megalin-
deﬁcient and megalin-expressing mice are summarized in Table 1.
Tracer accumulation in the blood, spleen, liver and muscle was not
signiﬁcantly different in both groups. Renal uptake of the tracer in
megalin-deﬁcient mice was 44.21 3.46% lower compared with
megalin-expressing animals (p< 0.05). These data conﬁrmed the
imaging data and show thatmegalin plays an important role in the
renal retention of 99mTc-7C12.
3.4. Reduction of renal retention of 99mTc-7C12 by
gelofusine and lysine in CD-1 mice
Lysine preload did not signiﬁcantly reduce the kidney uptake of
99mTc-7C12 compared with the control animals (Fig. 4). However,
a clear reduction of 25.1 7.3% was measured when lysine was
coadministered with the tracer. Injection of gelofusine at the time
of tracer injection also resulted in a strong reduction of kidney
uptake: 36.2 7.5%. There was no additional effect of lysine
preload on the reduction caused by gelofusine administration
(p> 0.05). The combination of lysine and gelofusine at the time
of injection resulted in the strongest reduction, namely 44.2
5.1% (p< 0.05, compared with lysine coadministration), although
this did not reach statistical signiﬁcance compared with gelo-
fusine coadministration.
3.5. Effect of combined gelofusine and lysine
administration on the biodistribution of 99mTc-7C12 in mice
bearing a tumor xenograft
Mice were injected either with 99mTc-7C12 alone (negative
control) or 99mTc-7C12 in combination with lysine and gelofusine
(LysCoadþGeloCoad). Total body pinhole SPECT/microCT was
acquired at 1 h p.i. of the compounds. As shown in Fig. 5(A),
LysCoadþGeloCoad resulted in less tracer accumulation in the
kidneys compared with the control (75.75 4.99 vs 126.41
12.20%IA g1). Tumor uptake of the tracer was signiﬁcantly higher
in LysCoadþGeloCoad compared with control (p< 0.05; Fig. 5A).
The activity in the liver and muscle was similar in both groups.
Tracer elimination was signiﬁcantly higher in LysCoadþGeloCoad
than in control group (40.01 1.61 vs 17.58 1.00 respectively,
p< 0.05). These data show that reduction of renal uptake of
99mTc-7C12 by the combination of gelofusine and lysine does not
negatively affect tumor uptake or the retention in background
tissues. The ex vivo analysis of mice bearing A431 xenograft
injected either with 99mTc-7C12 alone (control) or 99mTc-7C12 in
Figure 1. Ex vivo autoradiogram of renal tissue of a nude mouse
injected with 99mTc-7C12 and euthanized at 1 h p.i.. The radioactivity is
mainly concentrated in the renal cortex.
Figure 2. Analytical Size Exclusion Chromatography-High Pressure Liquid Chromatography (SEC-HPLC) chromatograms of 99mTc-7C12. 99mTc-7C12 was
incubated in PBS for 1 h (A) or 24 h (B) at room temperature. In parallel, 99mTc-7C12 was incubated in serum for 6 h (C) and 24 h (D) at 378C. Only onemajor
peak of radioactivity with the same retention time (27min) was observed.
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combination with lysine and gelofusine (LysCoadþGeloCoad) at
1.5 h p.i. is summarized in Table 2. The ex vivo data conﬁrmed the
image data described above. LysCoadþGeloCoad signiﬁcantly
reduced renal uptake of 99mTc-7C12 by 42.83 3.15% compared
with control. As shown by image analysis, there was no signiﬁcant
difference in the accumulation of the tracer in the liver, spleen
and muscle (p> 0.05); however tumor uptake of the tracer
was signiﬁcantly higher in LysCoadþGeloCoad treated mice
which also reﬂected the tumor-to-background ratios. The tumor-
to-muscle ratio for LysCoadþGeloCoad and control group was
32.81 1.76 vs 26.74 4.61 (p> 0.05); the tumor-to-blood ratio
was 7.83 1.65 vs 5.69 0.98 (p> 0.05) respectively.
The blood clearance curves were biphasic, showing fast
and similar elimination in both groups (Fig. 6). The calculated a
and b-half-lives were 0.19 and 4.68min for control, respectively,
and 0.18 and 3.89min for LysCoadþGeloCoad treated mice,
respectively.
4. DISCUSSION
In the development of new tracers it is important to show high
afﬁnity and speciﬁc binding of the tracer to the molecular target
both in vitro and in vivo. It is equally important for a tracer to
Figure 3. Pinhole SPECT/microCT images of megalin-wildtype (A) and
megalin-knockout mice (B) at 1 h p.i. of 99mTc-7C12. NIH color scale is used
and images are equally scaled to correct for injected activity.
Table 1. Biodistribution of 99mTc-7C12 in megalin-knockout and megalin-wild-type mice euthanized at 1.5 h p.i.
Tissue/organ
Megalin-knockout Megalin-wild-type
Weight (g) %IA g1 Weight (g) %IA g1
Blood 0.15 0.06 0.28 0.04 0.14 0.03 0.31 0.04
Kidneys 0.20 0.01 131.51 8.17* 0.17 0.01 235.79 7.67
Spleen 0.18 0.01 0.41 0.02 0.11 0.01 0.47 0.09
Liver 1.27 0.08 0.91 0.07 1.18 0.09 1.13 0.03
Muscle 0.11 0.02 0.17 0.03 0.13 0.01 0.15 0.06
Skin 0.14 0.02 0.21 0.06 0.14 0.02 0.35 0.06
Heart 0.25 0.08 0.19 0.02 0.15 0.02 0.23 0.02
Mouse 26.60 1.01 ND 22.10 0.76 ND
Data are presented as means standard error of the mean.
*Signiﬁcantly different (p< 0.05), n¼ 5 for each group.
ND, not determined.
Figure 4. Reduction of renal retention of 99mTc-7C12 in CD-1 mice. Mice
received pre- or co-administration of lysine alone or in combination with
gelofusine and were euthanized at 1.5 h p.i. of 99mTc-7C12. The total
activity in the kidneys was quantiﬁed and the percentage of reduction
was calculated. *Statistically signiﬁcant compared to lysine preload
p< 0.05, Ap< 0.05 compared to lysine coadministration. Data are
shown as mean SEM. Lysine preload at 30min before tracer injection
(LysPreload), (lysine preload at 30min before tracer injectionþgelofusine
coadministration with the tracer (LysPreloadþGeloCoad), lysine coadmi-
nistration with the tracer (LysCoad), gelofusine coadministration with the
tracer (GeloCoad) and lysine plus gelofusine coadministration with the
tracer (LysCoadþGeloCoad).
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exhibit favorable biodistribution and pharmacokinetics for it to
be translated into a clinical application. The ideal tracer only
accumulates at the target and is rapidly cleared from non-target
tissues. Clearance can be hepatic and/or renal. Hepatic and
subsequent intestinal elimination is to be avoided for cancer
targeting probes because it obscures liver metastasis and
intra-abdominal lesions. Kidney clearance with urinary elimin-
ation is preferable. This requires relatively hydrophilic molecules
with a molecular size that is inferior to 60 kDa threshold for
glomerular ﬁltration. Nanobodies ﬁt this description: they are
hydrophilic, have a molecular size of 15 kDa, have a fast blood
clearance and show low liver uptake (10). Together with their
characteristic of speciﬁc targeting with afﬁnities in the nanomolar
range, they represent an interesting class of probes for the
generic development of molecular imaging agents. The main
disadvantage at present is the relatively high kidney retention.
This problem is common to most small proteins or peptide
tracers. The kidney retrieves useful substances from the glome-
rular ﬁltrate and radiometal-chelated amino acids are trapped,
leading to high absorbed doses of radiation (12). Since the
radiation dose to the kidney might be a dose-limiting factor in
Figure 5. (A) Pinhole SPECT/microCT images of mice bearing A431 xenografts acquired at 1 h p.i. showing less tracer uptake in the kidneys (top panel)
and higher activity in the tumor of LysCoadþGeloCoad treated mice (bottom panel). NIH color scale is used and images are equally scaled to correct for
the injected activity. (B) Image quantiﬁcation depicting signiﬁcantly higher uptake in the tumor of LysCoadþGeloCoad treated mice. Data shown are
mean SEM. *Signiﬁcant p< 0.05.
Table 2. Biodistribution of 99mTc-7C12 injected either alone (control) or in combination with lysine and gelofusine (Lys-
CoadþGeloCoad) in mice bearing a tumor xenograft euthanized at 1.5 h p.i.
Tissue/organ
LysCoadþGeloCoad Control
Weight (g) %IA g1 Weight (g) %IA g1
Blood 0.34 0.07 0.70 0.05 0.42 0.05 0.68 0.08
Kidneys 0.26 0.01 68.95 3.76* 0.26 0.01 120.61 6.91
Spleen 0.16 0.01 0.94 0.39 0.12 0.01 1.19 0.29
Liver 1.48 0.05 2.55 0.66 1.41 0.10 3.50 0.77
Muscle 0.13 0.01 0.16 0.02 0.14 0.02 0.15 0.02
Tumor 0.61 0.13 4.70 0.43* 0.46 0.06 3.54 0.25
Mouse 28.08 0.96 ND 28.08 1.53 ND
Data are presented as mean standard error of the mean.
*Signiﬁcantly different (p< 0.05), n¼ 6 for each group.
ND, not determined.
Figure 6. Blood clearance of 99mTc-7C12 in Control (n¼ 6) and Lys-
CoadþGeloCoad (n¼ 6) in mice with a xenograft bearing A431 tumour.
Blood samples were collected at indicated time points, their activity was
determined with a gamma-counter and expressed as percentage of the
administered activity per total blood volume (%IA/TBV). Biologigal half-
life in plasma was determined using a two phase biexponential decay of
nonlinear regression ﬁt (GraphPad Prism).
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nanobody imaging and therapy, optimization of the tumor
radiation dose while avoiding too much radiation damage to the
kidneys is very necessary and will enlarge therapeutic window.
The kidney retention of radiopharmaceuticals is not only
dependent on the characteristics of the targeting molecule
itself, but is also dependent on the type of chelator or radio-
nuclides and on the stability of the radiolabeled compound
(25,26). We used nanobody-labeled site speciﬁcally with
technetium tricarbonyl ([99mTc(CO)3(H2O)3]
þ) via its hexahistidine
tag inserted genetically for immobilized metal ion afﬁnity
chromatography puriﬁcation purpose. [99mTc(CO)3(H2O)3]
þ easily
changes its three water molecules for a wide variety of donor
ligands including histidine to form a stable complex. Here we
have shown that 99mTc7C12 is extremely stable in vitro in human
serum while in kidneys the radiotracer is metabolized to some
extent. Nanobody retention is mainly localized in the kidney
cortex. Using a megalin-knockout mouse model we could prove
that this mechanism is responsible for at least 40% of the total
retention in the kidneys. We also showed that it is feasible to
reduce kidney retention without negatively affecting targeted
tumor uptake using gelofusine and lysine administration. Renal
reabsorption of proteins is predominantly mediated by megalin
and cubilin receptors. Both are endocytic receptors that are
expressed on the apical side of proximal tubule cells. They are
co-localized in the clathrin-coated pits of the brush border and
undergo endocytosis with trafﬁcking towards the lysosomes (27).
In the lysosomes, proteins are degraded into amino acids that are
subsequently released at the basolateral side into the peritubular
capillaries. Megalin can bind and internalize ligands, whereas
cubilin requires the presence of megalin for internalization.
Both receptors interact with a wide variety of ligands and accept
multiple ligands simultaneously (28,29). The afﬁnity of the
interaction is variable but the efﬁciency of the process is related
to the high expression levels, allowing for high capacity reabsorp-
tion. Some proteins bind both receptors; others are speciﬁc for
one receptor (28,29). From our study in megalin-knockout mice
we can clearly show that megalin is at least partially related to the
renal retention of 99mTc-7C12 nanobody. The relation might even
be stronger than the 44% that we showed because the knockout
is not complete and a low level of megalin is still present in these
animals (30). The total renal retention also varies between
different animal strains. Megalin-wild-type had almost two-fold
higher renal retention compared with athymic nude mice.
Therefore the 40% involvement of megalin might not be
predictive for all animal strains and species or even human. Since
cubilin requires megalin for internalization we also cannot
distinguish what receptor 99mTc-7C12 actually binds. However it
does open the possibility of interfering with this mechanism in
order to reduce kidney retention. Infusion of positively charged
amino acids, succinylated gelatin (gelofusine) or albumin frag-
ments that competitively interact with the megalin/cubilin
mediated recognition of radiolabeled peptides or antibody
fragments can reduce renal retention (31–33). Some of these
approaches are clinically validated and have become part of the
standard protocols in peptide receptor radionuclide therapy
(33,34). However, this principle is not applicable to all compounds
and efﬁciency can vary greatly between different types of
radiolabeled compounds (35). Here we show that this principle
does apply for 99mTc-7C12 nanobody. Coadministration of lysine
and/or gelofusine at the time of tracer administration effectively
reduces the kidney retention by approximately 40%. The combi-
nation of gelofusine and lysine showed the strongest reduction,
although we could not show strong statistical signiﬁcance
compared with gelofusine alone. The infusion of these compounds
did not increase the retention of the tracer in the body but
effectively directed the renal ﬁltered nanobodies towards
elimination via the urinary bladder. This was calculated using
total body microSPECT imaging that allows an exact measure-
ment of the residual total body activity. Here we measured
an extra 20% urinary elimination of the injected activity at 1 h
post-injection that is related to the gelofusine plus lysine
coadministration. Higher tumor uptake was observed in animals
that received gelofusine plus lysine coadministration. It is known
that gelofusine increases cardiac output and thereby might also
increase the blood ﬂow (36) and the delivery of nanobody to the
tumor. As a result tumor-to-background ratios were also better
after gelofusine and lysine administration.
Other mechanisms are probably also involved in the reabsorp-
tion. These include a variety of organic ion transporters (37) and
ﬂuid phase endocytosis (pinocytosis), which is not receptor
mediated. For the latter mechanism it is not possible to interfere
speciﬁcally but increasing urine production through hydration of
the subject might reduce this pathway. Such hydration is always
beneﬁcial for reducing the residence time of most radiolabeled
probes in the kidneys and urinary system.
An alternative approach for reducing radionuclide trapping in
the kidney is the use of different chelator and radioisotopes
or the introduction of a speciﬁc spacer sequence between the
targeting probe and the radionuclide. Such a spacer can be
designed so that it is enzymatically cleaved in the kidney, thereby
releasing the radionuclide from the protein (38,39). The intro-
duction of a spacer sequence is compatible with the nanobody
format and an interesting option for future research.
In summary, 99mTc-labeled 7C12 nanobody is intensively
accumulated in the renal cortex. The endocytotic receptor
megalin is involved in this accumulation, which can be partially
inhibited by coinfusion of gelofusine and/or lysine with the tracer.
Although this methodology allows for optimization of imaging
protocol using nanobodies, further improvements are needed
before using these molecules for radionuclide therapy.
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